Olivier Christophe
68
Documents
Publications
Publications
A consistent in vivo factor VIII-equivalence is unlikely to exist for non-factor therapiesCongrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France
Communication dans un congrès
hal-04701045
v1
|
|
L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand44ème congrès de la Société Française d'Hématologie, Société Française d'Hématologie, Mar 2024, Paris, France. pp.P327, Abstract 18-03
Communication dans un congrès
inserm-04541054
v1
|
|
L'angiopoïétine-2 se lie à de multiples sites interactifs au sein du facteur von Willebrand44e congrès annuel de la Société Française d’Hématologie, Société Française d’Hématologie, Mar 2024, Paris, France. p 327, abstract 18-03
Communication dans un congrès
hal-04654288
v1
|
|
Fitusiran-treatment modulates the ratio between alpha- and beta-antithrombin isoformsCongrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France
Communication dans un congrès
hal-04701035
v1
|
|
Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiencyWorld Federation of Hemophilia, World Federation of Hemophilia, Apr 2024, Madrid, Spain
Communication dans un congrès
hal-04654270
v1
|
|
Llama-derived single-domain antibodies blocking tissue factor pathway inhibitor and increasing thrombin generation in FVIII- and FX-deficient plasmaEuropean Congress on Thrombosis and Haemostasis, Sep 2023, Valence (Espagne), Spain
Communication dans un congrès
hal-04501177
v1
|
|
A single-domain antibody enhancing protein S activity reduces vaso-occlusion in two murine models of sickle cell diseaseEuropean Congress on Thrombosis and Haemostasis, Sep 2023, Valence (Espagne), Spain
Communication dans un congrès
hal-04501174
v1
|
|
|
|
A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia aASH abstracts, Nov 2022, San Diego (CA), United States. pp.677-678, ⟨10.1182/blood-2022-169482⟩
Communication dans un congrès
hal-04501469
v1
|
Antithrombotic Potential of a Single-domain Antibody Enhancing the Anticoagulant Activity of Protein SHybrid Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2021, Philadelphia (Pennsylvania), United States. pp.Abstract OC 60.2
Communication dans un congrès
hal-04501112
v1
|
|
Transplacental Delivery of Maternal FVIII for Induction of FVIII-specific Immune ToleranceHybrid Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2021, Philadelphia (Pennsylvania), United States. pp.Abstract OC 14.1
Communication dans un congrès
hal-04501088
v1
|
|
Caractérisation d’une nanobody qui potentialize l’activité cofacteur de la protéine C active de la protéine S40ème congrès de la Société Française d’Hématologie, Société Française d’Hématologie, Sep 2020, Paris, France. pp.Page 39, Abstract 04-01
Communication dans un congrès
hal-04501074
v1
|
|
p.(Pro2145Thrfs*5) et p.(Cys2216Phefs*9), deux Nouvelles mutations identifiées dans le domaine D4 du facteur von Willebrand chez des patientes d’origine afro-caribéenne40ème congrès de la Société Française d’Hématologie, Société Française d’Hématologie, Sep 2020, Paris, France. p 50, Abstract 05-07
Communication dans un congrès
hal-04501081
v1
|
|
A inducible mouse model of Factor X deficiency to test novel FX therapeuticsXXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. pp.Abstract OC 28.4
Communication dans un congrès
hal-04499851
v1
|
|
Von Willebrand factor induces human vascular smooth muscle cells proliferation through low density lipoprotein-related receptor 4 and alphavbeta3 integrinXXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia
Communication dans un congrès
hal-04498513
v1
|
|
Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia AXXVIIth Congress of the International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. pp.Abstract OC 75.3
Communication dans un congrès
hal-04498448
v1
|
|
Développement d’un modèle de souris avec un déficit inductible en facteur X39th Congress of the Société Française d’Hématologie, Société Française d’Hématologie, Mar 2019, Paris, France. pp.Abstract 12-29
Communication dans un congrès
hal-04498403
v1
|
|
The potential use of nanobodies delivered via AAV vectors in the treatment of hemophilia21st Annual Meeting of the American Society of Gene and Cell Therapy, American Society of Gene and Cell Therapy, May 2018, CHICAGO, United States
Communication dans un congrès
hal-04457494
v1
|
|
La Protéase Nexine-1, un inhibiteur physiologique de la thrombine, cible potentielle dans le traitement de l’hémophilie.38th Congress of the Société Française d’Hématologie, Société Française d’Hématologie, Mar 2018, PARIS, France. p 133, Abstract 12-59
Communication dans un congrès
hal-04457483
v1
|
|
Targeting Protease Nexin-1, a natural anticoagulant to control bleeding in hemophilia A2nd European Congress on Thrombosis and Haemostasis, Oct 2018, Marseille, France
Communication dans un congrès
hal-04457505
v1
|
Protein engineering in FLT210, a Potent Next Generation AAV-hFVIII Vector CandidateProtein Engineering Summit PEGS, Aug 2020, Boston - online, United States
Poster de conférence
hal-04461544
v1
|
|
Transplacental delivery of maternal factor VIII for induction of immune tolerance to therapeutic factor VIIIVirtual Congress of the International Society on Thrombosis and Haemostasis, Jul 2020, Milan (Virtual), Italy. Res. Pract. Thromb. Haemost, 4 (Suppl. 1), pp.Abstract PB0177, 2020
Poster de conférence
hal-04501045
v1
|
|
Development of single domain antibodies targeting protease nexin-1 as a strategy for hemophilia treatmentXXVIIth Congress of the International Society on Thrombosis and Haemostasis, Jul 2019, Melbourne (AUS), Australia. Res. Pract. Thromb. Haemost, 3 (Suppl. 1), pp.Abstract PB0316, 2019
Poster de conférence
hal-04499858
v1
|
|
Modulation of the platelet count by Romiplostim and inhibitors of LIM kinase in genetically-engineered von Willebrand disease type 2B mice: in vivo evaluation of haemostatic efficiency.ECTH, 2018, Oct 2018, Marseille, France
Poster de conférence
hal-04455308
v1
|
|
|
Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate61 ASH Annual Meeting, Blood, 134 (Supplement_1), pp.4638-4638, 2019, ⟨10.1182/blood-2019-128490⟩
Proceedings/Recueil des communications
hal-04461585
v1
|
|
|
Thrombin-mediated activation of factor VIII is insufficient to produce all necessary cofactor activity in vivoCongress of the International Society of Thrombosis and Haemostasis, Research and Practice in Thrombosis and Haemostasis, 3, pp.1-891, 2019, ⟨10.1002/rth2.12229⟩
Proceedings/Recueil des communications
hal-04461945
v1
|
Chargement...
Chargement...